Evidence map›Paper›PMID 28693754›Full record

ArticleSchizophrenia research2017

A comprehensive analysis of mitochondrial genes variants and their association with antipsychotic-induced weight gain.

Kirti Mittal, Vanessa F Gonçalves, Ricardo Harripaul, Ari B Cuperfain, Brandi Rollins, Arun K Tiwari, Clement C Zai, Malgorzata Maciukiewicz, Daniel J Müller, Marquis P Vawter and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Schizophrenia research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. ACAD10 and ACAD11 allow entry of 4-hydroxy fatty acids into β-oxidation.Cellular and molecular life sciences : CMLS · 2024
    Article
  5. Effects of antipsychotic drugs on energy metabolism.European archives of psychiatry and clinical neuroscience · 2024
    Article
  6. Article
  7. Observational
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Kirti MittalNeurogenetics Laboratory, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, ON, Canada.
Vanessa F GonçalvesNeurogenetics Laboratory, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, ON, Canada. Electronic address: Vanessa.Goncalves@camh.ca.
Ricardo HarripaulInstitute of Medical Sciences, University of Toronto, ON, Canada; Molecular Neuropsychiatry & Development (MiND) Lab, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Ari B CuperfainNeurogenetics Laboratory, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, ON, Canada.
Brandi RollinsFunctional Genomics Laboratory, Department of Psychiatry and Human Behavior, University of California, Irvine, CA, USA.
Arun K TiwariNeurogenetics Laboratory, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, ON, Canada.
Clement C ZaiNeurogenetics Laboratory, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, ON, Canada.
Malgorzata MaciukiewiczNeurogenetics Laboratory, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, ON, Canada.
Daniel J MüllerNeurogenetics Laboratory, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, ON, Canada.
Marquis P VawterFunctional Genomics Laboratory, Department of Psychiatry and Human Behavior, University of California, Irvine, CA, USA.
James L KennedyNeurogenetics Laboratory, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, ON, Canada.
University of Toronto · CACentre for Addiction and Mental Health · CAUniversity of California, Irvine · US

Funding

Mitochondrial Dysfunction In SchizophreniaR01MH085801 · NIMH · UNIVERSITY OF CALIFORNIA-IRVINE · PI VAWTER, MARQUIS PHILIP · 2009 to 2020
$5.0M
Mitochondrial Deletions in Mood DisordersR21MH099440 · NIMH · UNIVERSITY OF CALIFORNIA-IRVINE · PI VAWTER, MARQUIS PHILIP · 2013 to 2014
$424k
NIMH NIH HHS R01 MH085801NIMH NIH HHS R21 MH099440
6 · The paper itself

Abstract

Antipsychotic Induced Weight Gain (AIWG) is a common and severe side effect of many antipsychotic medications. Mitochondria play a vital role for whole-body energy homeostasis and there is increasing evidence that antipsychotics modulate mitochondrial function. This study aimed to examine the role of variants in nuclear-encoded mitochondrial genes and the mitochondrial DNA (mtDNA) in conferring risk for AIWG. We selected 168 European-Caucasian individuals from the CATIE sample based upon meeting criteria of multiple weight measures while taking selected antipsychotics (risperidone, quetiapine or olanzapine). We tested the association of 670 nuclear-encoded mitochondrial genes with weight change (%) using MAGMA software. Thirty of these genes showed nominally significant P-values (<0.05). We were able to replicate the association of three genes, CLPB, PARL, and ACAD10, with weight change (%) in an independent prospectively assessed AIWG sample. We analyzed mtDNA variants in a subset of 74 of these individuals using next-generation sequencing. No common or rare mtDNA variants were found to be significantly associated with weight change (%) in our sample. Additionally, analysis of mitochondrial haplogroups showed no association with weight change (%). In conclusion, our findings suggest nuclear-encoded mitochondrial genes play a role in AIWG. Replication in larger sample is required to validate our initial report of mtDNA variants in AIWG.

Indexed as

DNA, MitochondrialGenes, MitochondrialPharmacogenomic VariantsAdultAntipsychotic AgentsBenzodiazepinesFemaleGenome-Wide Association StudyHumansMaleOlanzapinePharmacogenomic TestingProspective StudiesQuetiapine FumarateRisk FactorsRisperidoneAntipsychotic AgentsBenzodiazepinesDNA, MitochondrialOlanzapineQuetiapine FumarateRisperidoneAntipsychotic-induced weight gainMitochondriaMitochondrial DNA variantsNext generation sequencingNuclear-encoded mitochondrial genesSchizophrenia

Identifiers

PMID28693754
PMCPMC5660917
OpenAlexW2730832154

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.